A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

NCT04027309 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

777

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndrome With Excess Blasts-2

Interventions

DRUG: Gilteritinib
DRUG: Midostaurin

Sponsor

Stichting Hemato-Oncologie voor Volwassenen Nederland

Collaborators

[object Object]
[object Object]